Search
We investigated the suggestion that otitis-prone children have an impaired antibody response in the context of pneumococcal vaccination.
Clinical Research Manager
Researchers at The Kids Research Institute Australia have helped map the global impact of life saving vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation (EPI).
Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain.
Children in low-mid income countries, and First Nations children in high-income countries, experience disproportionately high rates of Streptococcus pneumoniae and Haemophilus influenzae infections and diseases including pneumonia and otitis media.
Despite widespread use of pneumococcal conjugate vaccines (PCVs) in children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In addition, many children do not complete their PCV course on schedule. V114 is a 15-valent PCV that contains two epidemiologically important serotypes, 22F and 33F, in addition to the 13 serotypes present in PCV13, the licensed 13-valent PCV.
To investigate the long-term impact of recurrent otitis media (rOM) and ventilation tube insertion (VTI) in early childhood on hearing outcomes and middle-ear health three to five years later, in a prospective pregnancy cohort study.
In 2017, a steep rise in cases of meningococcal disease caused by the W strain sparked a wave of concern for parents in Western Australia.
New mothers in Perth are teaming up with researchers at The Kids Research Institute Australia in a global bid to develop the first vaccine to prevent Respiratory Syncytial Virus (RSV) disease.
Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Honorary and NHMRC Career Development Fellow, Paediatric Infectious Diseases Physician and Clinical Microbiologist